Live attenuated oral vaccine against ETEC and typhoid fever
Inventors
Wu, Yun • Kopecko, Dennis J. • Sim, B. Kim Lee • Hoffman, Stephen L.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
Core Innovation
The invention relates to a transgenic Salmonella typhi Ty21a that comprises an integrated heterologous enterotoxogenic Escherichia coli (ETEC) antigen biosynthetic gene region together with a heterologous acid resistance biosynthetic gene system. The heterologous gene regions and systems are integrated into the Salmonella typhi Ty21a chromosome so that an ETEC antigen is stably expressed from the integrated heterologous ETEC antigen biosynthetic gene region and the heterologous acid resistance enzymes are stably expressed.
The heterologous acid resistance biosynthetic gene system comprises one or more heterologous Shigella acid resistance enzymes, including a YbaS gene. The transgenic Salmonella typhi Ty21a is more acid stable at pH 2.5 than Salmonella typhi Ty21a without the integrated heterologous acid resistance biosynthetic gene system.
Claims Coverage
The document contains one independent claim, centered on a transgenic Salmonella typhi Ty21a strain with chromosomal integration of a heterologous ETEC antigen biosynthetic gene region and a heterologous Shigella acid resistance biosynthetic gene system, including a YbaS gene, with increased acid stability at pH 2.5.
Chromosomal integration of heterologous ETEC antigen and Shigella acid resistance systems
A transgenic Salmonella typhi Ty21a comprising a heterologous enterotoxogenic Escherichia coli (ETEC) antigen biosynthetic gene region and a heterologous acid resistance biosynthetic gene system comprising one or more heterologous Shigella acid resistance enzymes, wherein said heterologous ETEC antigen biosynthetic gene region and said heterologous acid resistance biosynthetic gene system are integrated into the Salmonella typhi Ty21a chromosome.
Stable expression of integrated ETEC antigen
An ETEC antigen is stably expressed from said integrated heterologous ETEC antigen biosynthetic gene region.
Stable expression of heterologous Shigella acid resistance enzymes including YbaS
Said one or more heterologous Shigella acid resistance enzymes are stably expressed; and said one or more heterologous Shigella acid resistance enzymes of the heterologous acid resistance biosynthetic gene system comprises a YbaS gene.
Improved acid stability at pH 2.5 compared with Ty21a lacking the integrated acid resistance system
Said transgenic Salmonella typhi Ty2a is more acid stable at pH 2.5 than Salmonella typhi Ty21a without the integrated heterologous acid resistance biosynthetic gene system.
Overall, the claim coverage is directed to a single integrated genetic system in Salmonella typhi Ty21a that combines stable heterologous ETEC antigen expression with stably expressed Shigella acid resistance enzymes, including YbaS, and a measurable acid stability improvement at pH 2.5 versus Ty21a without the integrated acid resistance system.
Stated Advantages
Increased acid stability at pH 2.5 compared with Salmonella typhi Ty21a without the integrated heterologous acid resistance biosynthetic gene system.
Documented Applications
A vaccine made from the composition of the pharmaceutical composition, formulated to be suitable for oral administration.
Elicitation of an immune response against a Salmonella typhi challenge by the transgenic Salmonella typhi Ty21a.
A pharmaceutical composition comprising the transgenic Salmonella typhi Ty21a together with a pharmaceutically suitable carrier.
Interested in licensing this patent?